Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma

被引:10
作者
Kim, Hee Nam [1 ]
Yu, Li [1 ]
Kim, Nan Young [1 ]
Lee, Il-Kwon [1 ]
Kim, Yeo-Kyeoung [2 ]
Yang, Deok-Hwan [2 ]
Lee, Je-Jung [2 ]
Shin, Min-Ho [3 ]
Park, Kyeong-Soo [4 ]
Choi, Jin-Su [3 ]
Kim, Hyeoung-Joon [1 ,2 ]
机构
[1] Chonnam Natl Univ, Hwasun Hosp, Genome Res Ctr Hematopoiet Dis, Jeollanamdo, South Korea
[2] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Jeollanamdo, South Korea
[3] Chonnam Natl Univ, Sch Med, Dept Prevent Med, Kwangju, South Korea
[4] Seonam Univ, Coll Med, Dept Prevent Med, Namwon, South Korea
关键词
TUMOR-SUPPRESSOR GENE; LUNG-CANCER RISK; COLORECTAL-CANCER; MYELOID-LEUKEMIA; BREAST-CANCER; P53; MUTATIONS; ARG72PRO; SUSCEPTIBILITY; PROGRESSION;
D O I
10.1002/ajh.21834
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymorphism of TP53 Arg72Pro is associated with many different cancers [1-4]. Few studies have investigated its role in the susceptibility to non-Hodgkin lymphoma (NHL) [5,6]. To examine the association between this polymorphism and NHL risk, we conducted a Korean large-scale, population-based case-control study (945 cases and 1,700 controls). The TP53 72 CC genotype was associated with increased risk of NHL (P=0.04) and diffuse large B-cell lymphoma (P=0.04). Our findings provide evidence that the TP53 Arg72Pro is associated with an increased risk of NHL in Korea.
引用
收藏
页码:822 / 824
页数:3
相关论文
共 28 条
[1]   Association of the germline TP53 R337H mutation with breast cancer in southern Brazil [J].
Assumpcao, Juliana G. ;
Seidinger, Ana Luiza ;
Mastellaro, Maria Jose ;
Ribeiro, Raul C. ;
Zambetti, Gerard P. ;
Ganti, Ramapriya ;
Srivastava, Kumar ;
Shurtleff, Sheila ;
Pei, Deqing ;
Zeferino, Luiz Carlos ;
Dufloth, Rozany M. ;
Brandalise, Silvia Regina ;
Yunes, Jose Andres .
BMC CANCER, 2008, 8 (1)
[2]  
Bergamaschi G, 2004, HAEMATOLOGICA, V89, P868
[3]  
Boltze C, 2002, INT J ONCOL, V21, P1151
[4]   TP53 and breast cancer [J].
Borresen-Dale, AL .
HUMAN MUTATION, 2003, 21 (03) :292-300
[5]   TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors [J].
Bumroongkit, Kanokkan ;
Rannala, Bruce ;
Traisathit, Patrinee ;
Srikummool, Metawee ;
Wongchai, Yannawan ;
Kangwanpong, Daloroong .
CANCER GENETICS AND CYTOGENETICS, 2008, 185 (01) :20-27
[6]   The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].
Dumont, P ;
Leu, JIJ ;
Della Pietra, AC ;
George, DL ;
Murphy, M .
NATURE GENETICS, 2003, 33 (03) :357-365
[7]   MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility [J].
Ellis, Nathan A. ;
Huo, Dezheng ;
Yildiz, Ozlem ;
Worrillow, Lisa J. ;
Banerjee, Mekhala ;
Le Beau, Michelle M. ;
Larson, Richard A. ;
Allan, James M. ;
Onel, Kenan .
BLOOD, 2008, 112 (03) :741-749
[8]   The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain [J].
Fernandez-Rubio, Aida ;
Felicitas Lopez-Cima, M. ;
Gonzalez-Arriaga, Patricia ;
Garcia-Castro, Laura ;
Pascual, Teresa ;
Marron, Manuel G. ;
Tardon, Adonina .
LUNG CANCER, 2008, 61 (03) :309-316
[9]   MOLECULAR-BASIS FOR HETEROGENEITY OF THE HUMAN P53-PROTEIN [J].
HARRIS, N ;
BRILL, E ;
SHOHAT, O ;
PROKOCIMER, M ;
WOLF, D ;
ARAI, N ;
ROTTER, V .
MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (12) :4650-4656
[10]   The p53 pathway: positive and negative feedback loops [J].
Harris, SL ;
Levine, AJ .
ONCOGENE, 2005, 24 (17) :2899-2908